NCT07597005

Brief Summary

The objective of this study is to evaluate the effects of red propolis on inflammation and oxidative stress in patients with chronic kidney disease on conservative management.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for not_applicable

Timeline
15mo left

Started Sep 2025

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress34%
Sep 2025Aug 2027

Study Start

First participant enrolled

September 30, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 30, 2025

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

May 12, 2026

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 19, 2026

Completed
1.3 years until next milestone

Study Completion

Last participant's last visit for all outcomes

August 31, 2027

Expected
Last Updated

May 19, 2026

Status Verified

May 1, 2026

Enrollment Period

2 months

First QC Date

May 12, 2026

Last Update Submit

May 12, 2026

Conditions

InflammationKidney DiseaseOxidative StressChronic Kidney Disease

Keywords

oxidative stressred propolisinflammationchronic kidney disease

Outcome Measures

Primary Outcomes (1)

  • Change in inflammatory biomarkers

    Changes in the IL-6 and TNF-α

    8 weeks

Study Arms (2)

Red Propolis Group

EXPERIMENTAL

Patients with chronic kidney disease will receive capsules containing 200mg of red propolis / day for two months.

Dietary Supplement: Red Propolis

Placebo Group

PLACEBO COMPARATOR

Patients with chronic kidney disease will receive capsules containing 200mg of placebo/ day for two months.

Other: Placebo Control

Interventions

Red PropolisDIETARY_SUPPLEMENT

Participants will receive 200mg of red propolis capsules per day for two months.

Red Propolis Group
Placebo ControlOTHER

Participants will receive 200mg of placebo capsules per day for two months.

Placebo Group

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • patients with CKD stages 3-5 under conservative management

You may not qualify if:

  • pregnant,
  • lactating,
  • smoker
  • patients using antibiotics and antioxidant supplements in the last three months
  • patients with autoimmune and infectious diseases,
  • patients with cancer, liver disease, and AIDS

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Denise Mafra

Rio de Janeiro, Rio de Janeiro, 22260050, Brazil

RECRUITING

MeSH Terms

Conditions

Kidney DiseasesRenal Insufficiency, ChronicInflammation

Condition Hierarchy (Ancestors)

Urologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesRenal InsufficiencyChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

Denise Mafra, phd

CONTACT

21985683003dmafra30@gmail.com

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
HEALTH SERVICES RESEARCH
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 12, 2026

First Posted

May 19, 2026

Study Start

September 30, 2025

Primary Completion

November 30, 2025

Study Completion (Estimated)

August 31, 2027

Last Updated

May 19, 2026

Record last verified: 2026-05

Locations

BR(1)